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Abstract  
Importance of the field 
Fas receptor is a mediator of the external apoptotic pathway in many cells and tissues. It is 
proposed to mediate osteoresorptive effects of estrogen deficiency and local/systemic 
inflammation.  
Areas covered in this review 
This review covers the past two decades of research on the expression and function of the 
Fas/Fas ligand system on bone cells, involvement in the pathogenesis of osteoresorption, and 
potential therapeutic modulation. 
What the reader will gain 
We review the structure, biological function and intracellular signaling pathways of the 
Fas/Fas ligand system, emphasizing the role of the non-apoptotic signaling pathways in bone 
cells, particularly osteoblast differentiation. We also present data on the in vitro expression 
and function of the Fas/Fas ligand system on osteoblast/osteoclast lineage cells, animal and 
human studies confirming its involvement in osteoresorptive disorders, and potential 
therapeutic approaches to modulate its function.  
Take home message 
Tissue specific therapeutic approaches need to be established to modify the Fas/Fas ligand 
system in osteoresorptive disorders, since systemic targeting has many side effects. The most 
promising approach would be to target Fas signaling molecules coupled with 
osteoblast/osteoclast differentiation pathways, but a precise definition of these targets is still 
needed. 
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1. Introduction 
 
1.1. Structure, expression and function of Fas and Fas ligand 
“Death receptor” is a term for members of the tumor necrosis factor (TNF) family of receptors 
responsible for the execution of the extrinsic apoptotic pathway and characterized by an 
intracellular α-helical protein-protein interaction domain named the death domain (DD). Eight 
members of the group have been described so far, including a prototypical death receptor Fas 
(FS-7-associated surface antigen; CD95; APO1; TNF receptor superfamily member 6, 
TNFRSF6). 
Fas is a type I transmembrane protein expressed by numerous healthy and tumor cells and 
tissues, including B and T lymphocytes, dendritic cells, thymocytes, macrophages, 
cardiomyocytes, hepatocytes, and various cells within the kidney, pancreas, and brain (1-3). 
The extracellular portion of the Fas protein comprises three cystein-rich domains 
characteristic for the TNF superfamily, while the intracellular portion includes the 
aforementioned death domain (4). A splicing variant of Fas lacks the transmembrane domain 
and is consequently shed as a soluble receptor, the form that probably has some regulatory 
functions, competing with membrane-bound Fas for Fas ligand (5). 
Fas is specifically activated by its ligand – Fas ligand (CD178; CD95L; APO1L; TNF ligand 
superfamily member 6, TNFSF6), a type II protein (6, 7). The expression of Fas ligand is 
more restricted, particularly to lymphocytes T (mainly CD8+ but also some CD4+) and 
natural killer (NK) cells (8). It is worth mentioning that Fas ligand is also substantially 
expressed by immunologically privileged tissues such as the eye, testis, and placenta (9).  
The primary or the most biologically active form of Fas ligand is a trimer on the cell surface 
but two other forms have also been documented. The extracellular, TNF-homologous domain 
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of Fas ligand can be cleaved from the membrane by metalloproteinases, thus resulting in a 
secreted trimer, which seems to be functionally quite inert and could have a regulatory role by 
occupying the binding sites on Fas (10). Furthermore, Fas ligand can also be secreted as 
membrane-bound, in a form of specific microvesicles, which are thought to be biologically 
active although their exact role is still not quite clear (11). Although the main receptor of Fas 
ligand is Fas, the decoy receptor 3 (DcR3), another member of the TNF receptor superfamily, 
is also able to bind Fas ligand, thus functioning as a regulator of the Fas–Fas ligand pathway 
(12). Interestingly, there are reports showing that Fas ligand per se can act as a receptor by 
reverse signaling through its intracellular tail (13).  
The first step of the Fas intracellular signaling pathway is the trimerization of Fas within the 
lipid rafts (14). Trimers of Fas–Fas ligand are subsequently oligomerized, which brings the 
intracellular parts of the Fas receptor in close proximity. This clustering triggers downstream 
signaling (Fig. 1): the DD of Fas binds a small adapter molecule, Fas-associated death domain 
(FADD)(15). FADD is characterized by the death effector domain (DED) which, through 
homotypic interactions, recruits pro-caspase-8 and pro-caspase-10, forming a death-inducing 
signaling complex (DISC), the molecular platform for initiation of Fas-mediated events (16). 
The formation of DISC results in autoproteolytic activation of caspase-8, and formation of an 
active caspase-8 heterotetramer which is released into the cytosol to activate the effector 
caspase-3 (17). Besides aforementioned, there are additional molecules which have been 
described to recruit to DISC (i.e. DAXX, FAP-1, FLASH, RIP, FAF-1), but their precise roles 
still need to be elucidated (18). DISC formation is an important regulatory instance of the Fas 
pathway where processing of procaspase-8 can be blocked by c-FLIP (cellular FLICE 
[=caspase-8, FADD-like interleukin-1β-converting enzyme] inhibitory protein), which 
interacts with FADD through DED (18). FADD can also bind to a transmembrane protein 
TOSO, another anti-apoptotic factor (19). 
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Subsequent intracellular events are the basis for the classification of cells in two types with 
respect to the involvement of the mitochondrial (internal) pro-apoptotic machinery (18). (Fig. 
1) Type I cells (such as lymphocytes) are characterized by abundant DISC formation, rapid 
activation of executor caspases and subsequent cell death. Type II cells (e.g. hepatocytes) are 
not as sensitive to Fas ligand, possibly because of an early exclusion of receptors from the 
lipid rafts (20). The amounts of activated caspase-8 are relatively low, so the apoptotic signal 
needs to be amplified through the internal (mitochondrial) apoptotic pathway (17). 
The ability of Fas to mediate cell death is best observed in the immune system, where it 
contributes to the shutdown of chronic immune responses and to the maintenance of 
peripheral tolerance, by a process known as restimulation-induced cell death (RICD) (21). 
Within the course of a prolonged immune response the availability of growth factors as well 
as diminished stimulation by antigen receptors make T and B cells susceptible to various 
apoptotic stimuli (16). Moreover, repeatedly stimulated cells upregulate their expression of 
Fas ligand (22) thus killing themselves (suicide) and neighboring T cells (fratricide) as well as 
B cells, dendritic cells, and macrophages (23, 24). In addition to the lymphocyte homeostasis, 
Fas–Fas ligand is an executive mechanism used by the effector arm of the immune response 
to combat infections. Fas ligand is expressed by both CD8+ T cells and NK cells (25) and it 
contributes mostly to the killing of virus-infected cells (26) and possibly some tumor cells 
(27). It is also worth to mention that CD4+ cells could suppress the CD8+ cells by the Fas 
pathway (28).  
Although apoptosis is the most striking outcome of Fas – Fas ligand interaction, their 
biological effects not based on cell death should be emphasized. Fas/Fas ligand interaction 
increases the production of chemokines in NK-T cells (29), increases also the activation of 
dendritic cells, and increases cellular proliferation (30). Fas ligand is a pro-survival factor for 
human CD34+ cells (31) and augments their colony-forming capacity (32).  
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Having in mind the various roles of the Fas–Fas ligand system, it is not surprising that its 
effects are not mediated only by the cells’ apoptotic machinery but via other signaling 
pathways as well. The intracellular portion of Fas receptor contains a tyrosine-containing 
motif tyrosine–x–x–leucine, similar to the canonical immunoreceptor-tyrosine-activation-
motifs (14). Upon ligand binding a phosphatydilinositol-3-kinase (PI3)-activation complex 
(PAC) is formed, with subsequent phosphorylation of a number of intracellular targets (33). 
Although the functional consequences are still poorly understood, this pathway is caspase-8-
independent, and does not lead to apoptosis but, at least in the model of a glioblastoma cell 
line, promotes cellular migration (14). Increased motility and invasiveness of tumor cell lines 
have also been described as a result of Fas-mediated activation of nuclear factor (NF) κB 
pathway (34). Depending on the subtle balance between procaspase-8 and c-FLIP at the 
DISC, engagement of Fas could lead to either caspase-mediated cell death, or triggering of 
NFκB signaling and cellular activation (35). Caspases are also confirmed to cleave the 
components of the NFκB pathway, and thus, regulate cellular proliferation responses (36). 
Finally, several groups reported on involvement of another major group of signaling 
molecules, i.e. mitogen activated protein kinases (MAPK) (37, 38) in Fas-mediated systems. 
 
2. Involvement of Fas in osteoresorption 
2.1. Expression and function of Fas on the cells of the skeletal system 
Bone remodeling is a continuous process in which bone is resorbed by osteoclasts and formed 
by osteoblasts, to maintain bone mass. Osteoblasts develop from mesenchymal progenitors 
present in bone marrow as well as in various tissues such as trabecular bone, fat, synovium, 
skin and umbilical cord blood (39). Osteoclasts develop from multipotent 
monocyte/macrophage hematopoietic progenitors whose differentiation towards the osteoclast 
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lineage is determined by binding of receptor activator of NF-κB ligand (RANKL) to the 
receptor activator of NF-κB (RANK) expressed on their surface (40).  
Many studies investigated the expression and function of Fas on cells involved in bone 
homeostasis. Fas is expressed on both murine and human osteoblasts (41, 42) and osteoclasts 
(43), but the data on the expression levels at certain osteoblast or osteoclast maturation stages, 
and function of Fas are conflicting.  
Several groups reported on the expression of Fas on mesenchymal stem cells as osteoblast 
progenitors. For instance, Fas protein expression has been confirmed by flow cytometry on 
human umbilical cord-derived mesenchymal stem cells (44), and several murine bone 
marrow-derived stromal cell lines, where agonistic antibodies were able to induce apoptosis 
(42). Strong expression of Fas gene was also detected in primary murine bone marrow-
derived stromal cells (45).  
Moreover, the expression of Fas on immature and mature osteoblasts was confirmed by a 
number of research reports. Strong constitutive expression of Fas has been demonstrated on 
the cells belonging to a human osteosarcoma cell line MG63, and primary human osteoblasts, 
where IgM anti-Fas antibody was able to induce apoptosis (46). In another report, MG63 cells 
and mature human osteoblasts differentiated from human mesenchymal cells weakly 
expressed Fas mRNA, as detected by gene-array hybridization (41). Murine preosteoblast 
MC3T3 cells did not express Fas (47). Expression of Fas gene seems to appear in mature 
osteoblasts, and increases in the calcification phase (48). On the protein level, as detected by 
flow cytometry, Fas appears on approximately one third of primary murine osteoblasts as they 
begin to differentiate and this percentage increases with osteoblast maturation (48).  
Data on the function of Fas expressed on osteoblast lineage cells are variable, which can be 
partially explained by the fact that the expression and function of Fas on the osteoblast lineage 
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cells may be affected by various cytokines and growth factors, which modify osteoblast 
sensitivity to Fas-induced apoptosis. Differences in expression and function of Fas among 
various studies can be ascribed to the variability in composition of animal sera and media 
used for cell culture among laboratories. For instance, IGF I added in vitro stimulates 
proliferation of human osteoblasts, but it also increases expression of Fas and induces 
apoptosis of proliferating osteoblasts (49). Although mouse preosteoblast cell line MC3T3 
does not express Fas in basal conditions, addition of TNF-α, interleukin (IL)-1β and 
interferon (IFN)-γ sensitize it to apoptosis induced by the addition of an agonistic anti-Fas 
antibody (47). Intracellular mechanisms involved in the regulation of the external apoptotic 
pathway may also modify the sensitivity of osteoblast lineage cells to Fas-induced apoptosis. 
E.g., vitamin 1,25(OH)2D3 is able to block anti-Fas antibody-induced primary human calvarial 
osteoblast apoptosis, interfering with the intracellular apoptotic signaling (50). MG63 cells 
express Fas, but presence of IFN-γ is required for Fas-induced apoptosis (51). According to 
our results, Fas activation induces apoptosis in both immature and mature bone marrow-
derived murine osteoblastogenic cultures, but not in all Fas-expressing cells. However, the 
addition of Fas ligand to osteoblastogenic cultures reduces the number of osteoblast colonies, 
which could not be ascribed to apoptosis, since the number of total colonies was not reduced. 
Partial resistance to apoptosis and the specific reduction in the number of osteoblast colonies 
suggests a non-apoptotic role of Fas in regulation of osteoblast differentiation and maturation 
(48). 
The data on Fas expression and function on osteoclast lineage cells are even more conflicting. 
Wu et al. found strong expression of Fas gene and protein in primary murine, human, and 
avian osteoclasts that increased with osteoclast differentiation (43). Moreover, human cord 
blood monocyte-derived osteoclasts have been shown to express Fas, and their apoptosis 
could be induced by the addition of anti-Fas agonist antibody (52). In other reports, Fas was 
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undetectable by flow cytometry in human peripheral blood–derived osteoclasts (53). 
According to our data, the transcriptional activity of Fas gene was almost absent in murine 
bone marrow-derived primary osteoclasts, and Fas protein was found to be weakly expressed 
on approximately 10% of these cells (48). Similar results were obtained by Park et al. who 
described a weak expression of both Fas and Fas ligand on primary murine bone marrow-
derived osteoclasts (54). Functional studies also provided contradictory results: increased 
osteoclast apoptosis is reported by Wu et al. upon addition of Fas-activating antibody to 
osteoclast cultures (43), whereas enhanced osteoclastogenesis was reported by Park at al. 
upon addition of recombinant Fas ligand, which was explained as a response to increased 
production of IL-1β and TNF-α by surrounding cells (54). There are additional reports 
showing a constitutive expression of Fas on murine bone marrow-derived osteoclasts, whose 
apoptosis may be induced by the up-regulation of Fas ligand by estrogen in the same cells 
(55). Expression and function of Fas is proposed to be biphasically regulated by RANKL 
(56). RANKL upregulates the expression of Fas in osteoclast progenitors, and may negatively 
regulate the size of the osteoprogenitor pool, whereas in mature osteoclasts, RANKL 
decreases expression Fas and prolongs their survival (56). 
The source of Fas ligand which can affect bone cells is still under debate but likely candidates 
are activated T and B lymphocytes, monocytes/macrophages, and NK cells (8). In addition, 
our group detected very low levels of Fas ligand mRNA and protein in murine osteoblasts and 
osteoclasts, i.e. within the cells of the bone milieu (48). However, according to Nakamura et 
al., Fas ligand is expressed by mature osteoclasts, and may be upregulated by estrogen which 
thus decreases their life span and prevents bone loss (55). On the other hand, Krum et al. 
documented, in vitro and in vivo, an estrogen-inducible expression of Fas ligand on osteoblast 
lineage cells. They also showed that osteoblasts are required for human pre-osteoclast 
apoptosis induced by estradiol suggesting that paracrine effects of FasL-expressing 
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osteoblasts are required for bone protective effects of estrogen (57). Several cytokines can 
modulate Fas expression and activation in osteoclasts, e.g. TNF stimulates osteoclastogenesis 
and increases osteoclastic expression of Fas in vitro (58). Conversely, presence of IL-12 or 
IL-18 may abolish increases in osteoclastogenesis induced by TNF, by upregulating Fas 
ligand in cultured cells (58, 59). 
 
2.2. Mouse models for studying the role of the Fas/Fas ligand system in osteoresorptive 
disorders 
Biological function of Fas and Fas ligand as regulatory molecules in the immune system has 
been confirmed and extensively studied using mouse models with spontaneous or induced 
mutations.  
There are two spontaneous mutation models for studying the Fas/Fas ligand system, and 
several induced mutations, i.e. knock-out models for either or both of the molecules. A 
spontaneous mutation in the coding for Fas ligand gene on chromosome 1 [a T-to-C transition 
point mutation that causes a replacement of a highly conserved phenylalanine with a leucine 
at position 273 in the extracellular region of the encoded protein (60)] has first been described 
in the C3H/HeJ strain (61). Mice homozygous for this mutation are unable to express a fully 
functional Fas ligand and develop lymphadenopathy and systemic autoimmune disorder, 
typically with enlargement of all lymph nodes, spleen, and increased numbers of T and B 
lymphocytes and dysregulation of their maturation and function (62). Due to their phenotype 
– generalized lymphoproliferative disorder – the mutant mice were named gld. A spontaneous 
mutation in the coding region of the Fas gene on chromosome 19 (63), first described in the 
MRL strain of mice (64), presents as a disorder very similar to the gld phenotype called a 
lymphoproliferative syndrome or lpr. One of the characteristics of both models is the 
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progressive accumulation of non-malignant CD4
–
CD8
–
 T lymphocytes. Because of the 
similarities of the two phenotypes it has early been postulated that these genes represented a 
receptor-ligand pair (65). 
Although both of these point mutations lead to an abolishment of Fas ligand and Fas function, 
respectively, it has been shown that both mutations may be leaky. The leakiness of the lpr 
mutation was shown (66) because small amounts of intact mRNA for Fas were found in 
immunocompetent tissues of lpr mice (e.g. thymus), and the leakiness of the gld mutation was 
long suspected because the gld phenotype did not correspond well to that of the Fas knock-out 
mutant mice (67). Hence, the introduction of knock-out strains (Fas-null mice by Adachi et al, 
and Fas ligand-null mice by Karray et al) helped to fully characterize the role of the system 
and the phenotype (68, 69). The most striking differences in phenotypes of induced models 
with a complete lack in Fas/Fas ligand signaling compared to mutant models are in the level 
of lymphoproliferation and the involvement of the liver; although the phenotypes are strain-
specific (e.g. the MRL strain shows the most severe phenotype). 
As the largest part of the cells of the skeletal system undergo apoptosis – up to 80% of 
osteoblasts (51), and most of osteoclasts (70), it has long been postulated that the Fas/Fas 
ligand system is involved in the regulation of, at least, some aspects of bone cell proliferation 
and cell death. As results of in vitro experiments on the expression and function of either 
molecule in cells of the skeletal system are often contradictory, mouse models lacking 
components of Fas/Fas ligand system have been used to study their regulatory effects on bone 
homeostasis. Since osteoresorptive disorders have a complex pathogenesis, involving several 
organ systems and multiple cellular interactions on various levels, studies on animal models 
of osteoresorption are necessary to confirm the physiological importance of a single molecule 
or molecular system in the pathogenic process. There are two widely used models for 
systemic and localized osteoresorption: 1) estrogen withdrawal by ovariectomy (ovx), and 2) 
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murine arthritic disease accompanied by localized osteodestruction and systemic 
osteoresorption. Estrogens are important regulators of both the immune system (71) as well as 
bone (72), and modification of levels of estrogen is an invaluable model for the analysis of the 
Fas/Fas ligand system (73). It has been shown in vivo that the disregulation in the Fas/Fas 
ligand system protects bones from the effects of estrogen withdrawal (55, 74, 75), i.e. bone 
loss. Joint destruction in arthritic diseases is a consequence of synovial hyperplasia which 
leads to formation of tissue-invasive pannus, increased osteoclastogenesis followed by 
localized bone resorption, and destruction of articular cartilage by inflammatory cells (76). 
Furthermore, hyperplastic synovia contains mesenchymal cells with a reduced ability to 
differentiate into mature mesenchymal lineage-cells (osteoblasts, chondroblasts, and 
adipocytes) (77). Impaired mesenchymal differentiation may be responsible for decreased 
osteoblastogenesis and may also contribute to subchondral bone loss in arthritis. However, 
studied on in vivo models, the role of Fas/Fas ligand system in the arthritic joint destruction is 
controversial, and points to the influence of genetic factors on the pathogenesis of arthritis. 
For example, the MRL-lpr mouse strain constitutively develops autoimmune arthritis in 
approximately 20% of animals (78). On the other hand, it has been shown that collagen 
induced arthritis is less severe in C57BL/6 mice with an lpr mutation and that this finding 
cannot be explained by the suppression of immune responses (79). Such differences can be 
also ascribed to the differences in cellular populations affected by Fas deficiency between 
different genetic backgrounds.  
 
2.3. The role Fas ligand/Fas system in human diseases 
Although the Fas/Fas ligand system has been recognized as one of the key pathways in 
controlling the proliferation and cell death in many sites and tissues, human diseases 
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involving mutations of components of this system are quite rare. These spontaneous mutations 
are described as an autoimmune lymphoproliferative syndrome (ALPS), and could be 
subdivided into four classes, with respect to the affected molecule (80). The syndrome is 
characterized by lymphadenopathy and splenomegaly, which are most often accompanied by 
autoimmune hemolytic anemia, thrombocytopenia and other autoimmune manifestations (81). 
In addition, the Fas/Fas ligand system has also been shown to contribute to several human 
autoimmune diseases such as autoimmune thyroiditis, systemic lupus erithematosus, and 
rheumatoid arthritis (82). Moreover, different studies point to the role of Fas/Fas ligand in the 
regulation of bone metabolism, implicating the role of Fas ligand/Fas malfunction in the 
pathogenesis of postmenopausal osteoporosis and osteoresorption in rheumatoid arthritis. 
Developing strategies to modulate these molecules for therapeutic purposes have become a 
promising challenge (83-85).  
Postmenopausal osteoporosis is the most common form of osteoporosis in which estrogen 
deficiency gives rise to an imbalanced high bone turnover, characterized by an enhanced 
osteoclast activity and a temporal increase in osteoblast activity which is not able to balance 
osteoclast-mediated bone resorption (86). Although various systemic and local regulators are 
involved in osteoporosis caused by estrogen deficiency, including activated T lymphocyte-
associated osteoclast stimulation by RANKL and TNF-α (87), the Fas/Fas ligand pathway 
emerged as an intriguing multifunctional regulatory system. In addition to data from animal 
models that implicated the role of Fas activation in osteoporosis following ovariectomy by 
several mechanisms (55, 57, 74, 75), some reports emphasized the importance of the Fas/Fas 
ligand system in the pathogenesis of human postmenopausal osteoporosis (88, 89). It has been 
shown that human postmenopausal osteoblasts constitutively express Fas receptors on cell 
surface, whose activation is able to induce their apoptosis (88). The same study also 
demonstrated that lethal effects of Fas ligand are exacerbated in the presence of TNF. 
  
13 
 
However, therapeutic concentrations of estradiol or of estrogen receptor modulator raloxifene 
analog did not affect the sensitivity of postmenopausal osteoblasts to Fas-mediated apoptosis. 
Nakamura et al (55) showed that estrogen induces apoptosis and upregulates Fas ligand 
expression in murine osteoclasts. As mentioned before the findings regarding the functional 
activity of Fas in human osteoclast differentiation and survival are still controversial (43, 52, 
53). Nevertheless, it is possible that estrogen regulates the life span of human osteoclasts via 
the induction of the Fas/Fas ligand system, offering the possibility that the induction of Fas 
would decrease bone resorption. In these circumstances, the likely sources of Fas ligand are 
immune cells, particularly activated T lymphocytes. Yamaza et al recently demonstrated 
osteoporosis mechanism in which activated T lymphocytes, via Fas pathway, induced both 
mouse and human bone-marrow mesenchymal stem cell apoptosis (89).  
Emerging evidence suggests that impaired Fas/Fas ligand system plays a role in the 
pathogenesis of rheumatoid arthritis (RA). The main feature of RA is synovial hyperplasia, 
which leads to cartilage and bone damage in the inflamed joints. Synoviocytes, synovial T 
lymphocytes and macrophages from arthritic joints express high levels of Fas and/or Fas 
ligand, and in vitro are highly susceptible to Fas/Fas ligand induced apoptosis (90). In 
contrast, resident synoviocytes are resistant to Fas-related apoptosis, probably reflecting the 
presence of multiple anti-apoptotic factors in the rheumatoid synovium, such as soluble Fas 
ligand and Fas, anti-apoptotic cytokines [transforming growth factor (TGF)–β, basic 
fibroblast growth factor (bFGF)] or Fas pathway inhibitors (matrix metalloproteinase (MMP)-
2, FLIP) (90). Moreover, immune cells within inflamed joints are resistant to Fas ligand-
mediated apoptosis, which leads to their accumulation and creates sustained inflammation that 
promotes osteoresorption (91). Reduced susceptibility to Fas-mediated apoptosis may also 
contribute to the expansion of an activated CD4
+
 T lymphocyte subpopulation and thus to the 
maintenance of peripheral autoreactive T lymphocyte clones in RA (92). In addition, our 
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group demonstrated decreased expression of Fas ligand in the peripheral-blood mononuclear 
cells of patients with RA, as well as a negative correlation of Fas ligand expression with the 
clinical assessment of disease activity (93). Furthermore, we also showed the non-apoptotic 
role of Fas in inhibition of osteoblast differentiation (48). Since proliferating, pannus-forming 
mesenchymal cells are resistant to apoptosis, Fas may, in these cells, have additional negative 
effects on subchondral bone loss, inhibiting osteoblastic bone formation. On the other hand, 
some authors suggested that susceptibility of RA osteoblasts to cytotoxic action of Fas ligand, 
produced by activated peripheral-blood mononuclear cells, underlies osteoporosis in RA (94). 
Similar to the animal models, the human studies also point to the still controversial role of the 
Fas/Fas ligand pathway in human disorders accompanied by osteoresorption, and caution is 
warranted in the use of Fas as a therapeutic target, as some patients with inflammatory 
arthritides may benefit from blockade, while others may benefit from agonism of Fas (95). 
 
2.4. Therapeutic approaches to modulate Fas/Fas ligand pathway in osteoresorptive 
disorders 
Osteoresorptive disorders develop when bone resorption by osteoclasts overcomes the bone 
formation by osteoblasts. Since Fas is shown to be expressed under various conditions on 
osteoblasts and osteoclasts, therapeutic approaches, both agonizing and antagonizing Fas 
signaling may be helpful in the treatment of osteoresorptive disorders, i.e. promoting Fas 
activation and apoptosis in osteoclasts, and inhibiting Fas mediated apoptosis in osteoblasts.  
Therapeutic approaches targeting the Fas/Fas ligand system which include systemic treatment 
with antibodies to Fas or with Fas ligand, revealed not to be a feasible strategy owing to the 
nonselective activation of Fas receptor on both, osteoblast and osteoclast lineage cells, as well 
as due to the hepato- and severe systemic-toxicity, pulmonary inflammation and fibrosis (84, 
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96, 97). There are relatively non-toxic modulators of the Fas death pathway which can be 
applied systemically, such as nonsteroidal anti-inflammatory drugs, methotrexate and anti-
TNF-directed therapies (98-101), and might prove interesting in the context of the role of Fas 
ligand/Fas system in bone homeostasis. A pharmacologic stem cell-based intervention by 
aspirin is also suggested as an approach for osteoporosis treatment, since T lymphocyte 
activation and Fas-induced mesenchymal stem cell apoptosis could be blocked by aspirin in 
vitro (89). Epidemiological studies reported that regular use of aspirin or non-steroidal anti-
inflammatory drugs may have a moderate beneficial effect on bone mineral density in 
postmenopausal women (98). However aspirin may contribute to multiple biological 
pathways, which makes it difficult to elucidate its precise functional mechanism in relation to 
bone remodeling.  
Direct targeting of osteoclast and osteoblast differentiation and influencing their life span to 
treat osteoresorptive disorders, including the modulation of the Fas ligand/Fas system, may be 
a more specific and potent therapeutic approach.  
As shown by studies related to Fas pathway modulation in cancer, Fas ligand gene may be 
directly delivered to target cells, with minimum systemic leakage (102). More recently, 
interfering RNA technology has been utilized to target gene expression of members of the 
extrinsic death receptor/Fas pathway in septic conditions, and the same approach may be used 
to target these members in osteoblast/osteoclast lineage cells. The experience with double 
stranded small interfering RNA (siRNA) against Fas and caspase-8 is an intriguing approach, 
but several limitations beyond cell targeting need to be resolved before siRNA can be applied 
clinically. Obstacles may include the induction of IFN signaling, since siRNA is a double 
stranded RNA, and subsequent unwanted inflammatory reactions (103).  
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As suggested by specific modulation of signaling pathways in tumors of tissue cells (18, 85, 
104, 105), tissue specific interventions directly aiming the Fas downstream signaling 
pathway, which is at the same time critical for osteoblast/osteoclast differentiation such as 
Raf/MEK/ERK, NF-κB and JNK/Jun, Wnt, and Smads, should be appreciated as more 
powerful and promising approaches (Fig. 2).  
Among the first were agonistic therapeutic interventions on Fas in arthritis, where 
hyperplastic synoviocytes destroy the subchondral bone. Since synovial inflammation is 
characterized by the unique resistance of proliferating synoviocytes to Fas-related apoptosis, 
Fas activation in these cells has drawn much attention as a possible tool to prevent joint 
destruction in both animal and human inflammatory arthritides (90). In line with this idea is 
the study that investigated apoptosis resistance caused by defects in the extrinsic and intrinsic 
apoptotic pathways in RA (106). Inhibition of PI3 kinase sensitizes RA fibroblast-like 
synovial cells to Fas-induced apoptosis by increasing cleavage of Bid protein, whose 
suppression is able to completely abrogate Fas-induced apoptosis. Bid overexpression 
increased the sensitivity of fibroblast-like synovial cells to Fas induced apoptosis, in 
association with cleavage of caspase-9. In RA fibroblast-like synovial cells, phosphorylation 
of Akt protects against Fas-induced apoptosis through inhibition of Bid cleavage. The study 
stressed that the connection between the extrinsic and the intrinsic apoptotic pathways is 
critical in Fas-mediated apoptosis and pointed to PI3 kinase as a potential therapeutic target 
for RA. Based on our recent findings in a mouse model of Fas deficiency, Fas activation 
seems to suppress osteoblast differentiation and contributes to osteoresorption in osteoporosis 
and subchondral bone loss in RA (48, 75). Inhibition of osteoblast differentiation was 
dependent on caspase-8 activation and resulted in down-regulation of expression of Runx2 
gene, one of the major transcription factors involved in osteoblast differentiation (107), 
suggesting that activated caspase-8 may have a specific regulatory function in osteoblast 
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lineage cells, and inhibition of caspase-8 may present an approach to prevent osteoresorption. 
A number of small molecule caspase inhibitors, such as IDN-6556, a pan-caspase inhibitor, 
are already in phase II clinical trials for treatment of liver disease (108). Regulatory function 
of caspases in osteoblast differentiation has already been confirmed for caspase-3, whose 
deficiency resulted in impaired osteoblastic differentiation of bone marrow stromal cells due 
to an overactivation of the TGF-β/Smad2 signaling pathway (109). Caspases may also inhibit 
the NF-κB survival pathway via the cleavage of the IκB kinase (IKK) complex scaffold 
protein and NF-κB modulator NEMO (36). The cleavage of intracellular proteins involved in 
differentiation pathways, may result in inadequate differentiation signals in osteoblast lineage 
cells, induced by Fas. Definition of caspase targets within these pathways may provide a 
specific pharmacological approach to counter-regulate osteoresorption.  
Having in mind that both Fas ligand and RANKL belong to the TNF superfamily of 
molecules, it is not surprising that in osteoclast lineage cells their intracellular signaling 
greatly overlaps (16, 110). It has been shown that their intracellular pathways interact with 
each other resulting in the modulation of Fas signaling by RANK engagement. RANKL 
provides osteoclast survival signals through several pathways, including c-src, PI3-
kinase/Akt, and the caspase cascade (56). RANKL also upregulates NF-κB activity in 
osteoclast precursors, as well as binding of NF-κB to the Fas promoter. RANK also signals by 
increasing Ca
2+
 influx and activation of the calmodulin-dependent phosphatase, calcineurin, 
which dephosphorylates nuclear factor of activated T-cells (NFAT), leading to NFAT 
translocation to the nucleus and activation of downstream osteoclast gene expression (Fig. 2). 
At the same time calmodulin regulates Fas-mediated apoptosis, at least in part, by binding to 
the death-inducing signaling complex inhibitor FLIP (111). Novel anti-resorptive drugs can 
target both Fas-mediated and RANKL-mediated pathways. For example, Ikarisoside A, 
isolated from Epimedium koreanum (Berberidaceae), has inhibitory effects on the RANKL-
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mediated activation of NF-κB, JNK, and Akt, decreasing the expression of c-Fos and 
NFATc1 as well as osteoclast-specific genes like matrix metalloproteinase 9 (MMP9), 
tartrate-resistant acid phosphatase (TRAP), RANK, and cathepsin K (112).  
 
2.5. Conclusions 
Fas is a member of the death receptor subgroup of the TNF receptor superfamily, activated 
upon binding of its ligand – Fas ligand that belongs to the TNF superfamily of ligands. The 
significance of the Fas/Fas ligand system has been extensively studied and recognized as 
important for the limitation of the chronic immune activation, maintenance of peripheral 
tolerance, and effector immune response. Since it is expressed by a variety of cells and 
tissues, including osteoblasts and osteoclasts at various differentiation stages, Fas may be 
involved in the regulation of their survival. Apoptosis has been considered as the main 
consequence of Fas activation, but there is increasing evidence that Fas activation may have 
additional regulatory, non-apoptotic functions in various cells and tissues.  
Although there are still many gaps in our knowledge and understanding of expression and 
function of Fas in cells of the skeletal system, animal models provide the evidence of Fas 
involvement in the regulation of bone homeostasis, and confirm the hypotheses that Fas 
inhibition may have osteoprotective effects in postmenopausal osteoporosis, as well as in 
rheumatoid arthritis. Studies performed on human subjects with osteoporosis and rheumatoid 
arthritis also support the involvement of Fas in the pathogenesis of these diseases.  
Therapeutic inhibition, or in some cases, activation of Fas receptor may be a promising 
approach in these conditions. However systemic anti-Fas therapy has many complications and 
side effects, and therefore, new therapeutic approaches have to be established to modify the 
Fas/Fas ligand system in human diseases. These approaches include the use of systemic 
modulators which also affect expression and function of Fas, gene therapy or iRNA. 
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However, a more specific therapeutic approach would target Fas intracellular signaling 
molecules coupled with pathways involved in osteoblast or osteoclast differentiation and 
activity, and their identification is required to fulfill this goal. 
 
3. Expert opinion 
Fas receptor is ubiquitously expressed in human and animal tissues, including skeletal tissue 
cells. However, the precise data on the expression and function of Fas on osteoblast and 
osteoclast lineage cells are still missing, mostly due to the fact that various reports provide 
different results and conflicting data, even in the same cell types and differentiation stages of 
bone cells.  
On the other hand, data obtained by animal models confirm that the blockage of Fas has a 
protective effect in osteoporosis, as well as in inflammation induced joint destruction and 
subchondral bone formation in RA. The precise mechanism underlying this protective effect 
is controversial and incompletely defined, since several research groups studying the effects 
of the Fas/Fas ligand system in bone metabolism provide various explanations based on their 
data.  
Osteoresorption is a consequence of either a decreased bone formation by osteoblasts or an 
increased bone resorption by osteoclasts. Among osteoresorptive disorders, osteoporosis and 
rheumatoid arthritis represent major public health problems due to their high morbidity and 
disability rates. Due to the complexity of both conditions, various therapeutic approaches 
have been used, which are either partially successful, or burdened with side effects and 
complications. Development of new therapeutic approaches to these conditions is an 
important area of research, where modification of Fas receptor-mediated effects may benefit 
the patients. 
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Cellular effects of Fas ligation vary, depending on several factors which may be 
therapeutically modified, including: a) surface expression and function of Fas, which can be 
altered by various intra- and extra-cellular stimuli, b) cell sensitivity to apoptosis, depending 
on the presence and activity of various anti-apoptotic molecules, and c) regulatory 
intracellular networks present and active in a specific cell, responsible for non-apoptotic 
responses in target cells.  
Direct therapeutic targeting of Fas is extremely difficult, due to its broad tissue expression, 
producing systemic effects. One of the specific approaches to target Fas in osteoresorptive 
disorders may involve cell therapy including ex vivo manipulation of Fas expression, or the 
quantity and activity of anti-apoptotic and regulatory molecules in osteoblasts, osteoclasts or 
their progenitors, which would aim to increase osteoclast apoptosis and/or decrease osteoblast 
apoptosis. However, these therapeutic approaches are also accompanied by various side 
effects and potentially dangerous consequences related to tumorigenicity of modified cells.  
Another approach is to define intracellular targets in skeletal cells and specific conditions (cell 
type, differentiation, activation stage) in which these targets are critical for the pathogenesis 
of osteoresorption, thus providing the possibility of pharmacological modulation of their 
responses to Fas activation. Modulation of apoptotic signaling has been extensively studied in 
various tumor cells where molecular interfering with survival pathways, such as JAK/Stat, or 
C-Raf-1, MEK-1 and Erk1/2 kinases, modifying Bcl-2 levels or the PI3K Akt activating 
pathway, may increase tumor cell sensitivity to conventional therapy. Additionally, caspases 
with their important role in cell apoptotic machinery, as well as due to their increasingly 
recognized signaling functions are also potential targets for pharmacological modulation of 
intracellular responses to Fas activation. Various synthetic or natural molecules with 
activating or inhibitory effects to the above mentioned pathways have been tested in pre-
clinical trials, and minor proportion of them such as Ikarisoside A or IDN-6556 has entered 
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Phase II clinical trials. This approach may also be beneficial in osteoresorptive disorders, 
through modifying the life span, differentiation, and activity of osteoblasts and osteoclasts. 
These alternative molecular components connecting Fas signaling and osteoblast/osteoclast 
differentiation and activity are still undefined and their functional importance still requires 
stronger evidence from preclinical studies. A better understanding of these pathways will 
clarify additional molecular mechanisms leading to osteoresorption, and contribute to the 
definition of new therapeutic targets. 
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Article highlights 
• Fas is a receptor from the TNF receptor superfamily, whose activation by binding of Fas 
ligand leads to apoptosis via external apoptotic pathway. Additionally, non-apoptotic 
effects of Fas signaling include regulation of cell proliferation, differentiation, and 
activation.  
• Expression and function of Fas on bone forming osteoblasts and bone resorbing osteoclasts 
has been extensively studied in vitro, but various reports often provide conflicting data. Fas 
and Fas ligand are shown to be expressed at certain stages of osteoblast and osteoclast 
differentiation, and their expression may be modified by various cytokines. Therefore, the 
Fas/Fas ligand system may be directly involved in the regulation of bone homeostasis.  
• Importance of Fas in osteoresorptive disorders has been confirmed in mice with loss-of-
function mutation in Fas, by two animal models of osteoresorption: estrogen withdrawal-
induced bone loss and collagen induced arthritis, a mouse model of human rheumatoid 
arthritis. These findings are in accordance with the results of several studies on 
postmenopausal osteoporosis and rheumatoid arthritis involving human subjects. 
• Since bone loss is a result of shifting the balance between bone formation by osteoblasts 
and bone resorption by osteoclasts towards resorption, therapeutic approaches promoting 
Fas activation and apoptosis in osteoclasts, and inhibiting Fas mediated apoptosis in 
osteoblasts, may be helpful in the treatment of osteoresorptive disorders. Systemic Fas 
targeting leads to nonselective activation of Fas receptor on both cell types and results in 
systemic toxic complications. A targeted approach may involve ex vivo manipulation of 
Fas expression in osteoblasts, osteoclasts or their progenitors; or definition of specific 
intracellular targets of Fas, involved in the regulation of life span, differentiation, and 
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activity of osteoblasts and osteoclasts, to pharmacologically treat osteoresorption.
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Figure 1. Schematic presentation of apoptotic pathways and their connection to cell 
proliferation and survival pathways.  
Fas receptor ligation initiates extrinsic apoptotic pathway which through its death domains 
(DD) binds small adapter molecule Fas-associated death domain (FADD) thus activating 
caspase-8 (or FLICE, FADD-like interleukin-1β-converting enzyme). The activated caspase-8 
further activates caspase-3 and other effector caspases which lead the cell into apoptosis. 
Apoptosis can at this level be prevented by c-FLIP (cellular FLICE inhibitory protein), 
attaching to DD.  
NFκB transcription factors promote cell growth and differentiation. They are activated usually 
through phosphorylation of inhibitory proteins IκB by IκB kinases (IKK) upon ligand binding 
of various receptors (i.e. RANKL on osteoclast lineage cells). In the nucleus, NFκB initiates 
transcription of inhibitors of apoptosis proteins (IAPs), which inhibit the effector caspase-3. 
On the other hand, binding of IAPs may be prevented by Smac/DIABLO or serine protease 
Omi, released from a mitochondria by an apoptotic stimulus.  
Mitochondria are involved in the intrinsic apoptotic pathway, initiated by cellular stress and 
leading to the release of cytochrome c from their internal membrane. Together with Apaf-1 
(apoptotic protease activating factor-1), cytochrome c forms an heptameric, caspase-9 
activating structure - apoptosome. Cytochrome c release is stimulated by the pro-apoptotic 
members of the Bcl-2 protein family from the Bax subfamily (i.e. Bid and Bad) which 
destabilize the outer mitochondrial membrane. Anti-apoptotic members (Bcl-2) prevent the 
activation and effects of the pro-apoptotic Bax proteins. Bax subfamily members may also 
activate caspases. On the other hand, caspase-8, cleaves and activates the Bid protein, thus 
transferring the signal from the extrinsic to the intrinsic apoptotic pathway (especially 
important in type II cells). 
 
  
Figure 2. Schematic presentation of osteoblast and osteoclast differentiation pathways 
and their connection with Fas downstream signaling pathways.  
Osteoblast differentiation is induced by several receptors, and leads to the activation of 
osteoblast transcription factors, including runt-related transcription factor 2 (Runx2), osterix, 
and Dlx5. Transforming growth factor-β (TGFβ) superfamily members (including bone 
morphogenetic proteins, BMPs) signal via serine/threonine receptor kinases and 
phosphorylation of Smad molecules. Phosphorylated Smads bind with the common Smad4 
and forming a trimeric structure which is translocated to the nucleus, where they induce 
transcription of osteoblast genes. TGFβ superfamiliy receptors also signal through mitogen 
activated protein kinase (MAPK) pathways. Fibroblast growth factor (FGF) receptor signals 
through cytoplasmatic parts possessing tyrosine kinase domains, activated upon 
conformational changes induced by ligand binding. They phophorylate and activate MAPK 
and protein kinase C (PKC). 
Wnt ligand binds to a frizzled (FZZ)/low density lipoprotein receptor related protein (LRP) 
complex, activating the intracellular protein dishevelled (DSH). DSH inhibits the activity of 
complex protein structure which transports β-catenin to the proteasome, and results in β-
catenin accumulation in the cytosol. β-catenin is then translocated to the nucleus where it 
regulates transcription.  
Ephrin (Eph) B4 is expressed on osteoblasts and signals through RhoA GTPase, while EphB2 
expressed on osteoclasts signals through PDZ proteins. Interaction of EphB2 and EphB4 
couples bone resorption to formation.  
Osteoclast differentiation is driven by several transcription factors, including nuclear factor of 
activated T-cells (NFATc1), Jun and Fos proteins, and NFκB. Receptor activator of nuclear 
factor (NF) κB (RANK) is a receptor from the tumor necrosis factor receptor (TNFR) 
superfamily, which is essential for osteoclastogenesis. Binding of its ligand (RANKL) 
activates various signaling pathways including NFκB, MAPK, c-Jun amino-terminal kinase 
(JNK), phospholipase Cγ (PLCγ), and phosphatidyl-inositol-3-kinase (PI3K). PI3K signaling 
links the RANK signaling pathway to the Akt proliferation and survival pathway. Binding of 
monocyte–colony stimulating factor (M-CSF) to its receptor (c-Fms) is essential for 
proliferation and survival of osteoclast precursors, and signals via PI3K/Akt and ERK. 
Additionally, signaling through the immunoglobulin (Ig)-like receptor, involving DAP12 
protein or FcRγ activates PLCγ, and induces calcium release, and transcription of osteoclast 
genes via calmodulin (CaM) and calcineurin. 
Yellow arrows point to the components of osteoblast and osteoclast differentiation pathways, 
which are proposed to be regulated by Fas signaling. 
 
 
 
